A new drug for pancreatic cancer takes the stage for clinical trials
What does it take to get to that moment in a clinic when a doctor gives a patient a compound never before used in modern medicine? The story of Minnelide, an investigational drug for pancreatic cancer patients now in a Phase IA clinical trial at the University of Minnesota, illustrates just how complex and exhilarating that journey can be.
Gamechanger: Gunda Georg
Gunda Georg is an esteemed researcher and professor who has made a tremendous impact in the field of synthetic medicinal chemistry.
Gunda Georg Inducted into the Academy for Excellence in Health Research
The Academy for Excellence in Health Research is the highest recognition of excellence in research by Academic Health Center faculty
Welcome to the Institute for Therapeutics Discovery & Development
ITDD creates opportunities for drug discovery and early pre-clinical drug development through collaborations between various schools, colleges and research centers, as well as industrial throughout Minnesota and nationwide.
Hormone-Free Birth Control Research Advances
Researchers will investigate pharmaceutical alternatives to existing hormone-based birth control under a new $8.3M NIH contract.
The Journal of Medicinal Chemistry
The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.
Dr. Peter Dosa Receives NIH Award
Dr. Peter Dosa has received a $190,625 NIH award for his project, "A pharmacological screen for inactivating antagonists."
The University of Minnesota Joins National Partnership Aimed at Expanding Biopharmaceutical Workforce and Industry
The University of Minnesota will join a team of academic institutions, private companies, governmental entities and non-profit organizations across the U.S.
Jon Hawkinson Received NIH Shared Instrumentation Award
Jon Hawkinson, director of the ITDD High-throughput Screening Laboratory, received a $343,887 NIH shared instrumentation award for the plasmon resonance (SPR) instrument, which will allowRead more...
Director, Institute for Therapeutics Discovery and Development
Professor and Department Head, Department of Medicinal Chemistry; Robert Vince Endowed Chair; McKnight Presidential Chair
Dr. Georg’s expertise includes synthetic medicinal agents, natural products chemistry, and the development of new synthetic methods. She is the co-inventor of Lusedra® and several other drug candidates, as well as the co-founder of ProQuest Pharmaceuticals, Inc. (now a part of Eisai Pharmaceuticals). The ITDD core directors have extensive academic and industrial drug discovery and development expertise. The group uses advanced research and development techniques, including high through-put screening, structure-based drug design, computer modeling, chem- and bioinformatics methods, and animal models to translate basic biomedical discoveries towards new approaches for prevention, treatment, and cures